TW200607505A - Fused heterocyclic kinase inhibitors - Google Patents

Fused heterocyclic kinase inhibitors

Info

Publication number: TW200607505A
Authority: TW; Taiwan
Prior art keywords: kinase inhibitors; fused heterocyclic; heterocyclic kinase; useful; protein kinase
Prior art date: 2004-06-28

Application number

TW094121488A

Other languages

English (en)

Inventor

Robert M Borzilleri

Zhong Chen

Tram N Huynh

Wayne Vaccaro

Xiao-Tao Chen

Kyoung S Kim

Zhen-Wei Cai

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-28

Filing date

2005-06-27

Publication date

2006-03-01

2005-06-27 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2006-03-01 Publication of TW200607505A publication Critical patent/TW200607505A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Virology (AREA)

TW094121488A 2004-06-28 2005-06-27 Fused heterocyclic kinase inhibitors TW200607505A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58345904P	2004-06-28	2004-06-28
US61256304P	2004-09-23	2004-09-23

Publications (1)

Publication Number	Publication Date
TW200607505A true TW200607505A (en)	2006-03-01

Family

ID=35457856

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TW094121497A TW200604184A (en)	2004-06-28	2005-06-27	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW094121488A TW200607505A (en)	2004-06-28	2005-06-27	Fused heterocyclic kinase inhibitors

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
TW094121497A TW200604184A (en)	2004-06-28	2005-06-27	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors

Country Status (14)

Country	Link
US (2)	US20050288290A1 (zh)
EP (3)	EP1771177A4 (zh)
JP (3)	JP2008504368A (zh)
KR (3)	KR20070037448A (zh)
AR (2)	AR049536A1 (zh)
AU (2)	AU2005260056B2 (zh)
BR (1)	BRPI0512722A (zh)
CA (1)	CA2571680A1 (zh)
IL (1)	IL180325A0 (zh)
MX (2)	MXPA06015032A (zh)
NO (3)	NO20070453L (zh)
PE (2)	PE20060524A1 (zh)
TW (2)	TW200604184A (zh)
WO (3)	WO2006004636A2 (zh)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7030112B2 (en) *	2003-03-25	2006-04-18	Bristol-Myers Squibb Company	Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US9169406B2 (en) *	2003-08-25	2015-10-27	Dow Global Technologies Llc	Coating compositions
ES2925655T3 (es)	2003-09-26	2022-10-19	Exelixis Inc	Moduladores c-Met y métodos de uso
DE10357510A1 (de) *	2003-12-09	2005-07-07	Bayer Healthcare Ag	Heteroarylsubstituierte Benzole
US7531532B2 (en)	2004-02-27	2009-05-12	Eisai R&D Management Co., Ltd.	Pyridine derivative and pyrimidine derivative
KR101298951B1 (ko)	2004-03-30	2013-09-30	버텍스 파마슈티칼스 인코포레이티드	Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한아자인돌
DE102004017438A1 (de) *	2004-04-08	2005-11-03	Bayer Healthcare Ag	Hetaryloxy-substituierte Phenylaminopyrimidine
US7459562B2 (en) *	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) *	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) *	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US20050288290A1 (en) *	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7432373B2 (en) *	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
AU2005270068B2 (en) *	2004-07-02	2012-04-19	Exelixis, Inc.	C-Met modulators and method of use
JP5096142B2 (ja) *	2004-07-30	2012-12-12	メチルジーンインコーポレイテッド	Ｖｅｇｆレセプターおよびｈｇｆレセプターシグナル伝達の阻害剤
US7504521B2 (en) *	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (es)	2004-08-12	2006-06-01	Bristol Myers Squibb Co	Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
US7569725B2 (en) *	2004-10-21	2009-08-04	Britsol-Myers Squibb Company	Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7151176B2 (en) *	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US8875040B2 (en) *	2005-06-07	2014-10-28	Rockwell Automation Technologies, Inc.	Universal web-based reprogramming method and system
TW200635927A (en) *	2004-12-22	2006-10-16	Bristol Myers Squibb Co	Synthetic process
AU2006229343A1 (en) *	2005-03-28	2006-10-05	Kirin Pharma Kabushiki Kaisha	Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
US7470693B2 (en) *	2005-04-21	2008-12-30	Bristol-Myers Squibb Company	Oxalamide derivatives as kinase inhibitors
JO2787B1 (en) *	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
DK1904504T3 (da) *	2005-05-20	2014-06-23	Methylgene Inc	Inhibitorer af vegf-receptor- og hgf-receptorsignalering
CA2611370C (en)	2005-05-20	2014-11-25	Oscar Mario Saavedra	Inhibitors of vegf receptor and hgf receptor signaling
US7402582B2 (en) *	2005-07-01	2008-07-22	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7232901B2 (en)	2005-07-01	2007-06-19	Bristol-Myers Squibb Company	Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7405213B2 (en) *	2005-07-01	2008-07-29	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
JP5072595B2 (ja)	2005-08-05	2012-11-14	中外製薬株式会社	マルチキナーゼ阻害剤
WO2007023768A1 (ja)	2005-08-24	2007-03-01	Eisai R & D Management Co., Ltd.	新規ピリジン誘導体およびピリミジン誘導体（３）
WO2007033196A1 (en) *	2005-09-14	2007-03-22	Bristol-Myers Squibb Company	Met kinase inhibitors
US7348325B2 (en) *	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
EP1973408A2 (en) *	2006-01-04	2008-10-01	Locus Pharmaceuticals, Inc.	Inhibitors of protein kinases
EP2001880A2 (en)	2006-03-07	2008-12-17	Array Biopharma, Inc.	Heterobicyclic pyrazole compounds and methods of use
WO2007107005A1 (en) *	2006-03-22	2007-09-27	Methylgene, Inc.	Inhibitors of protein tyrosine kinase activity
DK2010538T3 (da) *	2006-04-21	2013-03-18	Bristol Myers Squibb Co	Fremgangsmåde til fremstilling af [(1R), 2S]-2-aminopropionsyre 2-[4-(4-fluor-2-methyl-1H-indol-5-yloxy)-5-methylpyrrol]2,1-f-[1,2,4-triazin-6-yloxy]-1-methylethylester
TW200808763A (en)	2006-05-08	2008-02-16	Astrazeneca Ab	Novel compounds I
TW200808771A (en) *	2006-05-08	2008-02-16	Astrazeneca Ab	Novel compounds II
WO2008048375A1 (en) *	2006-05-19	2008-04-24	Bayer Healthcare Ag	Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
JP2009539878A (ja) *	2006-06-08	2009-11-19	アレイバイオファーマ、インコーポレイテッド	キノリン化合物および使用方法
EP2038272B8 (en) *	2006-06-30	2013-10-23	Sunesis Pharmaceuticals, Inc.	Pyridinonyl pdk1 inhibitors
AU2007288793B2 (en) *	2006-08-23	2012-04-19	Eisai R & D Management Co., Ltd.	Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
US7790885B2 (en)	2006-08-31	2010-09-07	Eisai R&D Management Co., Ltd.	Process for preparing phenoxypyridine derivatives
WO2008046216A1 (en) *	2006-10-18	2008-04-24	Methylgene, Inc.	Kinase inhibitors and uses thereof
US20100016307A1 (en) *	2006-10-27	2010-01-21	Toshihiro Hamajima	Novel compounds
PT2089364E (pt) *	2006-11-08	2013-08-26	Bristol Myers Squibb Co	Compostos de piridinona
CN101730699A (zh) *	2007-03-21	2010-06-09	百时美施贵宝公司	可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
EP2183255A4 (en) *	2007-08-29	2011-06-15	Methylgene Inc	METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF CONDENSED HETEROCYCLIC KINASE INHIBITORS
AU2008293038B2 (en) *	2007-08-29	2013-08-29	Mirati Therapeutics, Inc.	Inhibitors of protein tyrosine kinase activity
DE102007051762A1 (de)	2007-10-30	2009-05-07	Bayer Healthcare Ag	Substituierte Pyrrolotriazine und ihre Verwendung
CL2008003301A1 (es)	2007-11-06	2009-10-16	Astrazeneca Ab	Compuestos derivados de 3,4-dihidropirazina-2-carboxamida, inhibidores de la elastasa de neutrofilos humanos; composiciones farmacéuticas; procesos de preparación de compuestos y composición farmacéutica; y uso en el tratamiento de síndrome de dificultad respiratoria de los adultos, fibrosis quística, cáncer, entre otras.
WO2009061516A1 (en)	2007-11-08	2009-05-14	New York University School Of Medicine	Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
JP2009132660A (ja)	2007-11-30	2009-06-18	Eisai R & D Management Co Ltd	食道癌治療用組成物
KR101608096B1 (ko)	2008-01-23	2016-03-31	브리스톨-마이어스 스큅 컴퍼니	４-피리디논 화합물 및 암을 위한 그의 용도
AU2009206440B2 (en)	2008-01-23	2013-08-15	Bristol-Myers Squibb Company	4-pyridinone compounds and their use for cancer
BRPI0908573A2 (pt) *	2008-03-05	2012-12-25	Methylgene Inc	inibidores da atividade de proteÍna tirosina quinase
WO2009145814A2 (en) *	2008-03-10	2009-12-03	Vertex Pharmaceuticals Incorporated	Pyrimidines and pyridines useful as inhibitors of protein kinases
UY31984A (es) *	2008-07-16	2010-02-26	Boehringer Ingelheim Int	DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
UY31982A (es) *	2008-07-16	2010-02-26	Boehringer Ingelheim Int	Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
TWI365185B (en) *	2008-07-24	2012-06-01	Lilly Co Eli	Amidophenoxyindazoles useful as inhibitors of c-met
KR100961410B1 (ko) *	2008-10-14	2010-06-09	(주)네오팜	단백질 키나제 억제제로서 헤테로사이클릭 화합물
WO2010071885A1 (en)	2008-12-19	2010-06-24	Cephalon, Inc.	Pyrrolotriazines as alk and jak2 inhibitors
KR20250123237A (ko)	2009-01-16	2025-08-14	엑셀리시스, 인코포레이티드	암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
TW201036957A (en) *	2009-02-20	2010-10-16	Astrazeneca Ab	Novel salt 628
WO2011022028A2 (en) *	2009-05-18	2011-02-24	Tufts University	Small molecule antagonists of phosphatidylinositol-3, 4, 5-triphosphate (pip3) and uses thereof
PE20120508A1 (es)	2009-06-17	2012-05-09	Vertex Pharma	Inhibidores de la replicacion de los virus de la gripe
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PH12012500366A1 (en)	2009-08-24	2012-10-22	Ascepion Pharmaceuticals Inc	5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
EP2563773A1 (en)	2010-04-29	2013-03-06	Deciphera Pharmaceuticals, LLC	Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
KR101871436B1 (ko)	2010-05-17	2018-06-27	인코젠 쎄라퓨틱스 프라이빗 리미티드	단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
ES2573515T3 (es)	2010-06-25	2016-06-08	Eisai R&D Management Co., Ltd.	Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
EP2423208A1 (en) *	2010-08-28	2012-02-29	Lead Discovery Center GmbH	Pharmaceutically active compounds as Axl inhibitors
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
CA2844588A1 (en) *	2011-08-10	2013-02-14	Merck Patent Gmbh	Pyrido-pyrimidine derivatives
CN104321322A (zh)	2012-03-30	2015-01-28	理森制药股份公司	作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
TWI520962B (zh) *	2012-06-29	2016-02-11		As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
BR112015009004A8 (pt)	2012-12-21	2021-07-20	Eisai R&D Man Co Ltd	forma amorfa de derivado de quinolina e método de produção da mesma
WO2014115171A1 (en) *	2013-01-24	2014-07-31	Council Of Scientific & Industrial Research	Triazine compounds and a process for preparation thereof
US10517861B2 (en)	2013-05-14	2019-12-31	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PL3057969T3 (pl)	2013-10-17	2018-11-30	Blueprint Medicines Corporation	Kompozycje użyteczne do leczenia zaburzeń związanych z KIT
SI3421468T1 (sl)	2013-11-13	2021-03-31	Vertex Pharmaceuticals Incorporated	Postopki za pripravo inhibitorjev replikacije virusov influence
SG10201804026WA (en)	2013-11-13	2018-06-28	Vertex Pharma	Inhibitors of influenza viruses replication
HUE037579T2 (hu) *	2013-12-26	2018-09-28	Ignyta Inc	Pirazolo[1,5-a]piridin-származékok és módszerek alkalmazásukra
TW201613919A (en)	2014-07-02	2016-04-16	Pharmacyclics Llc	Inhibitors of Bruton's tyrosine kinase
JP6659554B2 (ja)	2014-08-28	2020-03-04	エーザイ・アール・アンド・ディー・マネジメント株式会社	高純度キノリン誘導体およびその製造方法
LT3263106T (lt)	2015-02-25	2024-01-10	Eisai R&D Management Co., Ltd.	Chinolino darinių kartumo sumažinimo būdas
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN106046007B (zh)	2015-04-07	2019-02-05	广东众生睿创生物科技有限公司	酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
EP3294735B8 (en)	2015-05-13	2022-01-05	Vertex Pharmaceuticals Incorporated	Inhibitors of influenza viruses replication
WO2016183116A1 (en)	2015-05-13	2016-11-17	Vertex Pharmaceuticals Incorporated	Methods of preparing inhibitors of influenza viruses replication
AU2016279474B2 (en)	2015-06-16	2021-09-09	Eisai R&D Management Co., Ltd.	Anticancer agent
SG11201801083UA (en)	2015-08-20	2018-03-28	Eisai R&D Man Co Ltd	Tumor therapeutic agent
EP3521276B1 (en)	2016-09-30	2021-03-10	Guangdong Raynovent Biotech Co., Ltd.	Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
WO2018145525A1 (zh) *	2017-02-08	2018-08-16	中国医药研究开发中心有限公司	吡咯并芳杂环类化合物及其制备方法和医药用途
CN110072528B (zh)	2017-02-08	2022-04-26	卫材R&D管理有限公司	治疗肿瘤的药物组合物
DK3583943T3 (da)	2017-02-15	2024-10-14	Taiho Pharmaceutical Co Ltd	Farmaceutisk sammensætning
WO2018183712A1 (en)	2017-03-31	2018-10-04	Blueprint Medicines Corporation	Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
KR20200013644A (ko)	2017-05-16	2020-02-07	에자이 알앤드디 매니지먼트 가부시키가이샤	간세포 암종의 치료
WO2018228923A1 (en) *	2017-06-13	2018-12-20	Bayer Pharma Aktiengesellschaft	Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
WO2019016071A1 (en)	2017-07-18	2019-01-24	Bayer Pharma Aktiengesellschaft	SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES
US12280045B2 (en)	2017-09-08	2025-04-22	Taiho Pharmaceutical Co., Ltd.	Antitumor agent and antitumor effect potentiator
TWI898556B (zh) *	2018-07-13	2025-09-21	美商基利科學股份有限公司	吡咯并[1,2-b]嗒衍生物
UY38349A (es)	2018-08-30	2020-03-31	Array Biopharma Inc	Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP7458406B2 (ja)	2018-12-21	2024-03-29	セルジーンコーポレーション	Ｒｉｐｋ２のチエノピリジン阻害剤
SMT202400229T1 (it)	2019-04-12	2024-07-09	Blueprint Medicines Corp	Derivati della pirrolotriazina per il trattamento delle malattie mediate da kit e pdgfra
MA53759A (fr)	2019-04-12	2021-08-04	Blueprint Medicines Corp	Formes cristallines de (s)-1-(4-fluorophényl)-1-(2-(4-(6-(1-méthyl-1h-pyrazol-4-yl))pyrrolo[2,1-f][1,2,4]triazin-4-yl)pipérazinyl)-pyrimidin-5-yl)éthan-1-amine et des procédés de fabrication
CN110407839B (zh) *	2019-07-01	2022-01-04	江西科技师范大学	含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
JP7636326B2 (ja) *	2019-07-29	2025-02-26	武田薬品工業株式会社	複素環化合物
TWI872203B (zh) *	2020-02-14	2025-02-11	日商大鵬藥品工業股份有限公司	醯基硫脲化合物的製造方法
CN113880845A (zh) *	2021-10-13	2022-01-04	广州六顺生物科技股份有限公司	吡咯并三嗪衍生物及其制备方法和应用
US12404242B2 (en)	2021-12-17	2025-09-02	Reglagene, Inc.	Compositions and methods for making and using small molecules in the treatment of cancer
CA3242732A1 (en) *	2021-12-29	2023-07-06	Beijing Avistone Biotechnology Co., Ltd.	Heteroaromatic nitrogen-oxide compound, preparation method therefor and use thereof
EP4673130A1 (en)	2023-02-28	2026-01-07	Reglagene, Inc.	Compositions and methods for making and using small molecules for the treatment of health conditions

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3646202A (en)	1967-11-22	1972-02-29	Merck & Co Inc	Liver fluke compositions containing salicylic acid derivatives
JPS54115384A (en)	1978-02-28	1979-09-07	Hokko Chem Ind Co Ltd	Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides
CH648611A5 (de)	1980-08-18	1985-03-29	Staeubli Ag	Verfahren und schaftmaschine zur gleichstellung aller schaefte einer webmaschine.
GB2106500B (en)	1981-09-18	1986-01-02	Dow Chemical Co	Method for making benzoylphenylureas
DE3139457A1 (de)	1981-10-03	1983-04-21	Bayer Ag, 5090 Leverkusen	Neue substituierte benzanilidether, verfahren zu ihrer herstellung, ihre verwendung als fungizide und zwischenprodukte hierfuer
DE3464368D1 (de)	1983-03-09	1987-07-30	Beecham Group Plc	Anti-inflammatory pyrazolo pyridines
EP0151962A3 (en)	1984-01-25	1985-10-02	Beecham Group Plc	Pyrazolopyridine derivatives
US4663341A (en)	1984-02-16	1987-05-05	Rohm And Haas Company	Insecticidal n-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides
GB8404584D0 (en)	1984-02-22	1984-03-28	Beecham Group Plc	Compounds
CH657015A5 (de)	1984-06-27	1986-08-15	Ciba Geigy Ag	Motten- und kaeferschutzmittel.
JPS6133176A (ja)	1984-07-24	1986-02-17	Ishihara Sangyo Kaisha Ltd	Ｎ−ニトロベンゾイル−ｎ’−ピリダジニルオキシフエニルウレア系化合物、それらの製造方法及びそれらを含有する抗癌剤
US4753940A (en)	1985-02-15	1988-06-28	Ciba-Geigy Corporation	Barbituric acid derivatives
JPS62135463A (ja)	1985-12-09	1987-06-18	Ishihara Sangyo Kaisha Ltd	Ｎ−ベンゾイルウレア系化合物、それらを含有する抗癌剤並びにそれらの製造方法
JPS625959A (ja)	1986-03-05	1987-01-12	Ishihara Sangyo Kaisha Ltd	ベンゾイルウレア系化合物
JPS625960A (ja)	1986-03-05	1987-01-12	Ishihara Sangyo Kaisha Ltd	ベンゾイルウレア系化合物の製造方法
JPS6262A (ja)	1986-03-05	1987-01-06	Ishihara Sangyo Kaisha Ltd	ベンゾイルウレア系化合物の製造方法
US4908056A (en)	1986-04-25	1990-03-13	E. I. Du Pont De Nemours And Company	Heterocyclic acyl sulfonamides
DE3830054A1 (de)	1988-09-03	1990-03-15	Boehringer Mannheim Gmbh	Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5132315A (en) *	1989-05-19	1992-07-21	The United States Of America As Represented By The Department Of Health And Human Services	Therapeutic application of an anti-invasive compound
EP0420804A3 (en)	1989-09-26	1991-11-27	Ciba-Geigy Ag	Anthelmintic compounds
SU1761753A1 (ru)	1990-07-16	1992-09-15	Ф. С. Михайлицын и Н. С. Уварова	5-(2-Хлор-4-нитро(амино)фенокси) бензо-2,1,3-тиадиазол в качестве промежуточного соединени в синтезе 5- @ 2-хлор-4-[(2-окси-3,5-дибромбензоил)амино]фенокси @ бензо-2,1,3-тиадиазола, про вл ющего активность при гименолепидозе белых мышей
US5646176A (en)	1992-12-24	1997-07-08	Bristol-Myers Squibb Company	Phosphonooxymethyl ethers of taxane derivatives
US6214344B1 (en)	1995-06-02	2001-04-10	Genetech, Inc.	Hepatocyte growth factor receptor antagonists and uses thereof
EP0874846B1 (en) *	1995-11-01	2003-04-02	Novartis AG	Purine derivatives and processes for their preparation
US6143764A (en) *	1995-11-07	2000-11-07	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
DE19710609A1 (de)	1997-03-14	1998-09-17	Bayer Ag	Substituierte Aminosalicylsäureamide
IL133800A0 (en)	1997-07-03	2001-04-30	Du Pont Pharm Co	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6022884A (en)	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
CN1280580A (zh) *	1997-11-11	2001-01-17	辉瑞产品公司	用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
US6362369B2 (en)	1997-11-25	2002-03-26	Nihon Nohyaku Co., Ltd.	Phthalic acid diamide derivatives fluorine-containing aniline compounds as starting material, agricultural and horticultural insecticides, and a method for application of the insecticides
TW515786B (en)	1997-11-25	2003-01-01	Nihon Nohyaku Co Ltd	Phthalic acid diamide derivatives, agricultural and horticultural insecticides, and a method for application of the insecticides
JP4253126B2 (ja)	1998-01-29	2009-04-08	アムジェンインコーポレイテッド	Ｐｐａｒ−ガンマ調節剤
US6232320B1 (en) *	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
CZ299375B6 (cs)	1998-11-30	2008-07-09	Nihon Nohyaku Co., Ltd.	Ftalamidové deriváty nebo jejich soli, zemedelsko-zahradnický insekticid je obsahující a jeho použití
US20020065296A1 (en)	1999-01-13	2002-05-30	Bayer Corporation	Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
ES2281591T3 (es)	1999-01-22	2007-10-01	Kirin Beer Kabushiki Kaisha	Derivados de n-((quinolinil)oxil)-fenil)-urea y de n-((quinazolinil)oxil)-fenil)-urea con actividad antitumoral.
KR100685336B1 (ko)	1999-02-22	2007-02-23	게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프)	Ｃ-21 변형 에포틸론
GB9904103D0 (en)	1999-02-24	1999-04-14	Zeneca Ltd	Quinoline derivatives
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
KR100666514B1 (ko)	1999-05-21	2007-02-28	브리스톨-마이어즈 스퀴브 컴페니	키나제의 피롤로트리아진 저해제
US6982265B1 (en) *	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
WO2000075145A1 (en)	1999-06-03	2000-12-14	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
AU780698B2 (en)	1999-07-20	2005-04-14	Dow Agrosciences Llc	Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
US6355660B1 (en)	1999-07-20	2002-03-12	Dow Agrosciences Llc	Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
GB9918035D0 (en) *	1999-07-30	1999-09-29	Novartis Ag	Organic compounds
KR20020032612A (ko)	1999-09-21	2002-05-03	다비드 에 질레스	퀴나졸린 유도체 및 그의 의약으로서의 용도
PL353791A1 (en)	1999-09-24	2003-12-01	Nihon Nohyaku Co, Ltd.Nihon Nohyaku Co, Ltd.	Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same
WO2001042243A2 (en)	1999-12-08	2001-06-14	Advanced Medicine, Inc.	Protein kinase inhibitors
US7135466B2 (en)	1999-12-24	2006-11-14	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives and drugs containing the same
US6750246B1 (en)	2000-02-03	2004-06-15	Bristol-Myers Squibb Company	C-4 carbonate taxanes
EP1149583A3 (en) *	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
DE60106022T2 (de)	2000-06-06	2006-03-09	Pfizer Products Inc., Groton	Thiophenverbindungen zur verwendung als antikrebsmittel
FR2812633A1 (fr)	2000-08-04	2002-02-08	Aventis Cropscience Sa	Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
DE60134679D1 (de)	2000-10-20	2008-08-14	Eisai R&D Man Co Ltd	Stickstoff enthaltende aromatische Heterozyklen
GEP20063915B (en)	2000-11-17	2006-09-11	Bristol Myers Squibb Co	PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
AU2002232439A1 (en)	2000-11-29	2002-06-11	Glaxo Group Limited	Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
CN1289072C (zh)	2000-12-22	2006-12-13	石原产业株式会社	苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
US6960580B2 (en) *	2001-03-08	2005-11-01	Millennium Pharmaceuticals, Inc.	Nitrogenous heterocyclic substituted quinoline compounds
US7081454B2 (en) *	2001-03-28	2006-07-25	Bristol-Myers Squibb Co.	Tyrosine kinase inhibitors
WO2003000194A2 (en)	2001-06-21	2003-01-03	Pfizer Inc.	Thienopyridine and thienopyrimidine anticancer agents
KR100883731B1 (ko)	2001-06-22	2009-02-12	기린 파마 가부시끼가이샤	간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
SE0102384D0 (sv)	2001-07-03	2001-07-03	Pharmacia Ab	New compounds
AU2002323743A1 (en)	2001-08-01	2003-02-17	Nissan Chemical Industries, Ltd.	Substituted amides and pest controllers
JP4383870B2 (ja)	2001-10-17	2009-12-16	協和発酵キリン株式会社	線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
JP2005510564A (ja)	2001-11-28	2005-04-21	藤沢薬品工業株式会社	アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
RU2316326C2 (ru) *	2001-12-03	2008-02-10	Байер Фамэсьютиклс Копэрейшн	Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины
JP2003321472A (ja)	2002-02-26	2003-11-11	Takeda Chem Ind Ltd	Ｇｒｋ阻害剤
US6900208B2 (en)	2002-03-28	2005-05-31	Bristol Myers Squibb Company	Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7388009B2 (en) *	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
AU2003231034B2 (en) *	2002-04-23	2009-03-05	Bristol-Myers Squibb Company	Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200306841A (en)	2002-04-23	2003-12-01	Bristol Myers Squibb Co	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200407143A (en)	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
TW200401638A (en)	2002-06-20	2004-02-01	Bristol Myers Squibb Co	Heterocyclic inhibitors of kinases
TW200409629A (en)	2002-06-27	2004-06-16	Bristol Myers Squibb Co	2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
TWI272271B (en) *	2002-07-19	2007-02-01	Bristol Myers Squibb Co	Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
EP1543009A4 (en)	2002-08-02	2007-08-08	Bristol Myers Squibb Co	Pyrrolotriazine KINASE INHIBITORS
AU2003284001A1 (en)	2002-10-07	2004-05-04	Bristol-Myers Squibb Company	Triazolone and triazolethione derivatives
CL2003002287A1 (es)	2002-11-25	2005-01-14	Wyeth Corp	COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
TW200427688A (en)	2002-12-18	2004-12-16	Glaxo Group Ltd	Antibacterial agents
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
JP2006516653A (ja)	2003-02-05	2006-07-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤ピロロトリアジンの製造方法
US7030112B2 (en) *	2003-03-25	2006-04-18	Bristol-Myers Squibb Company	Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
EP1641759B1 (en)	2003-07-07	2014-03-12	Merck Patent GmbH	Malonamide derivatives
ATE412655T1 (de)	2003-08-29	2008-11-15	Pfizer	Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
SE0302487D0 (sv)	2003-09-18	2003-09-18	Astrazeneca Ab	Novel compounds
ES2925655T3 (es)	2003-09-26	2022-10-19	Exelixis Inc	Moduladores c-Met y métodos de uso
US7419978B2 (en)	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
DE10357510A1 (de)	2003-12-09	2005-07-07	Bayer Healthcare Ag	Heteroarylsubstituierte Benzole
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7531532B2 (en)	2004-02-27	2009-05-12	Eisai R&D Management Co., Ltd.	Pyridine derivative and pyrimidine derivative
DE102004017438A1 (de)	2004-04-08	2005-11-03	Bayer Healthcare Ag	Hetaryloxy-substituierte Phenylaminopyrimidine
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) *	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) *	2004-06-09	2005-12-22	Pfizer Inc.	Ether-linked heteroaryl compounds
US7102002B2 (en) *	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US20050288290A1 (en) *	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7432373B2 (en) *	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW200600513A (en) *	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7504521B2 (en) *	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds

2005
- 2005-06-24 US US11/167,043 patent/US20050288290A1/en not_active Abandoned
- 2005-06-24 US US11/167,049 patent/US7173031B2/en not_active Expired - Lifetime
- 2005-06-27 TW TW094121497A patent/TW200604184A/zh unknown
- 2005-06-27 TW TW094121488A patent/TW200607505A/zh unknown
- 2005-06-28 WO PCT/US2005/022682 patent/WO2006004636A2/en not_active Ceased
- 2005-06-28 JP JP2007519416A patent/JP2008504368A/ja not_active Withdrawn
- 2005-06-28 MX MXPA06015032A patent/MXPA06015032A/es not_active Application Discontinuation
- 2005-06-28 WO PCT/US2005/023099 patent/WO2006004833A2/en not_active Ceased
- 2005-06-28 JP JP2007519322A patent/JP4860609B2/ja not_active Expired - Fee Related
- 2005-06-28 MX MXPA06015192A patent/MXPA06015192A/es active IP Right Grant
- 2005-06-28 BR BRPI0512722-0A patent/BRPI0512722A/pt not_active Application Discontinuation
- 2005-06-28 JP JP2007519390A patent/JP4782117B2/ja not_active Expired - Fee Related
- 2005-06-28 KR KR1020067027370A patent/KR20070037448A/ko not_active Ceased
- 2005-06-28 WO PCT/US2005/023198 patent/WO2006004884A2/en not_active Ceased
- 2005-06-28 EP EP05790229A patent/EP1771177A4/en not_active Withdrawn
- 2005-06-28 CA CA002571680A patent/CA2571680A1/en not_active Abandoned
- 2005-06-28 AU AU2005260056A patent/AU2005260056B2/en not_active Ceased
- 2005-06-28 KR KR1020067027376A patent/KR20070028458A/ko not_active Ceased
- 2005-06-28 EP EP05791275A patent/EP1761268A4/en not_active Withdrawn
- 2005-06-28 PE PE2005000754A patent/PE20060524A1/es not_active Application Discontinuation
- 2005-06-28 EP EP05764291A patent/EP1768983A2/en not_active Withdrawn
- 2005-06-28 KR KR1020067026897A patent/KR20070026621A/ko not_active Withdrawn
- 2005-06-28 AR ARP050102668A patent/AR049536A1/es not_active Application Discontinuation
- 2005-06-28 PE PE2005000752A patent/PE20060374A1/es not_active Application Discontinuation
- 2005-06-28 AR ARP050102669A patent/AR050254A1/es not_active Application Discontinuation
- 2005-06-28 AU AU2005259894A patent/AU2005259894C1/en not_active Ceased
2006
- 2006-12-25 IL IL180325A patent/IL180325A0/en unknown
2007
- 2007-01-24 NO NO20070453A patent/NO20070453L/no not_active Application Discontinuation
- 2007-01-26 NO NO20070514A patent/NO20070514L/no not_active Application Discontinuation
- 2007-01-26 NO NO20070506A patent/NO20070506L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2006004636A3 (en)	2006-05-26
NO20070514L (no)	2007-03-12
AR050254A1 (es)	2006-10-11
JP4860609B2 (ja)	2012-01-25
JP4782117B2 (ja)	2011-09-28
KR20070028458A (ko)	2007-03-12
US20050288290A1 (en)	2005-12-29
CA2571680A1 (en)	2006-01-12
EP1761268A4 (en)	2009-07-08
AR049536A1 (es)	2006-08-09
WO2006004884A3 (en)	2006-03-23
AU2005259894A1 (en)	2006-01-12
JP2008504368A (ja)	2008-02-14
PE20060524A1 (es)	2006-06-21
MXPA06015032A (es)	2007-02-08
EP1771177A2 (en)	2007-04-11
EP1768983A2 (en)	2007-04-04
BRPI0512722A (pt)	2008-04-01
NO20070453L (no)	2007-01-24
AU2005260056B2 (en)	2009-08-27
WO2006004636A2 (en)	2006-01-12
WO2006004833A2 (en)	2006-01-12
NO20070506L (no)	2007-02-14
JP2008504367A (ja)	2008-02-14
IL180325A0 (en)	2007-07-04
WO2006004884A2 (en)	2006-01-12
KR20070037448A (ko)	2007-04-04
US7173031B2 (en)	2007-02-06
WO2006004833A3 (en)	2006-07-13
US20060004006A1 (en)	2006-01-05
AU2005259894C1 (en)	2009-09-17
KR20070026621A (ko)	2007-03-08
AU2005260056A1 (en)	2006-01-12
PE20060374A1 (es)	2006-05-07
TW200604184A (en)	2006-02-01
MXPA06015192A (es)	2007-02-28
EP1771177A4 (en)	2009-07-29
EP1761268A2 (en)	2007-03-14
JP2008504366A (ja)	2008-02-14
AU2005259894B2 (en)	2009-03-19

Publication	Publication Date	Title
TW200607505A (en)	2006-03-01	Fused heterocyclic kinase inhibitors
IL260127B (en)	2022-04-01	mek inhibitors and methods of using them
ATE432281T1 (de)	2009-06-15	Pyrrolotriazin-kinasehemmer
ATE411022T1 (de)	2008-10-15	Pyridylpyrrol-derivate als wirksame kinase-hemmer
TW200833693A (en)	2008-08-16	Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
CY1114925T1 (el)	2015-12-09	Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
ATE371656T1 (de)	2007-09-15	Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE60333387D1 (de)	2010-08-26	Triazolopyridazine als proteinkinase-inhibitoren
IN2014KN02886A (zh)	2015-05-08
TW200801008A (en)	2008-01-01	Protein kinase inhibitors
ATE493418T1 (de)	2011-01-15	Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
ATE532789T1 (de)	2011-11-15	Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
ATE493401T1 (de)	2011-01-15	Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen
MX2007003603A (es)	2007-05-21	Metodos para preparar compuestos de indazol.
ATE546452T1 (de)	2012-03-15	Pyrazolopyrrolderivate als proteinkinaseinhibitoren
UA102219C2 (ru)	2013-06-25	Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
ATE287886T1 (de)	2005-02-15	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
DE60106409D1 (de)	2004-11-18	3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
EA200700692A1 (ru)	2007-08-31	Пиридиновые производные индолин-2-она, их получение и их прменение в терапии
UA96742C2 (en)	2011-12-12	Mek inhibitors and use thereof
UA91717C2 (en)	2010-08-25	Administration of 2-[[6-[(3r)-3-amino-l-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo- l(2h)-pyrimaidinyl]methyl]-benzonitrile for the treatment of conditions mediated with dipeptidyl peptidase inhibitors
TW200630345A (en)	2006-09-01	Methods for preparing indazole compounds